Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MoonLake Immunotherapeutics (MLTX : NSDQ)

• Company Description    MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON. Number of Employees: 130

• Price / Volume Information    Yesterday's Closing Price: $18.19 Daily Weekly Monthly 20 Day Moving Average: 920,172 shares Shares Outstanding: 71.73 (millions) Market Capitalization: $1,304.73 (millions) Beta: 1.01 52 Week High: $62.75 52 Week Low: $5.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.44% 2.19% 12 Week 2.88% -4.89% Year To Date 38.01% 28.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL DORFSTRASSE 29 - ZUG,V8 6300 CHE ph: 41-41-510-8022 fax: - ir@moonlaketx.com http://www.moonlaketx.com

• General Corporate Information    Officers Jorge Santos da Silva - Chief Executive Officer; Director Simon Sturge - Chairperson; Director Matthias Bodenstedt - Chief Financial Officer Spike Loy - Director Catherine Moukheibir - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 61559X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 71.73 Most Recent Split Date: (:1) Beta: 1.01 Market Capitalization: $1,304.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.93 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.71 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.14 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -55.56% vs. Previous Quarter: -6.52% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -85.15 12/31/25 - -66.56 09/30/25 - -55.57 ROA 03/31/26 - -60.52 12/31/25 - -50.23 09/30/25 - -45.18 Current Ratio 03/31/26 - 8.60 12/31/25 - 9.27 09/30/25 - 8.50 Quick Ratio 03/31/26 - 8.60 12/31/25 - 9.27 09/30/25 - 8.50 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 3.54 12/31/25 - 4.27 09/30/25 - 4.53 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.39 12/31/25 - 0.24 09/30/25 - 0.25 Debt-to-Capital 03/31/26 - 28.05 12/31/25 - 19.57 09/30/25 - 20.21

Powered by Zacks Investment Research ©